Furthermore, CYP1A1 is shown to have its own oncogenic function and promote prostate cancer proliferation and survival via dysregulation of BCL2. Altogether our findings demonstrate that tobacco smoking may contribute to the pathogenesis of prostate cancer and that inhibition of CYP1A1 may have therapeutic potential. The gene discussed is BCL2; the disease is prostate cancer.